LONA

LeonaBio, Inc.
CAPPED RATING

LeonaBio, Inc. (LONA) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B+
Factor Score 3.7 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
F
Factor Score 0.7 / 5.0
Momentum
D+
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA 0.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -53.2%
Price Return 12M -19.4%
Catalyst Signal 0.00
Market Cap $35.1M
TTM Revenue N/A
Price / Sales N/A
ROE -431.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B+ (3.7) D+ (1.8) F (0.7) D+ (1.5) C+ (2.6) C- (2.1)
2026-11-06 A- (3.9) D+ (1.8) F (0.7) D+ (1.8) C+ (2.7) C (2.2)
2026-10-30 B+ (3.7) D+ (1.8) F (0.7) D (1.3) C+ (2.7) C- (2.0)
2026-10-23 B+ (3.7) C- (1.9) F (0.6) C- (1.9) A+ (5.0) C+ (2.6)
2026-10-16 B+ (3.7) D+ (1.8) F (0.6) C (2.3) A+ (5.0) C+ (2.7)
Page 1 of 4